atezolizumab + olaparib

A combination therapy consisting of atezolizumab, a humanized monoclonal antibody targeting PD-L1, and olaparib, a PARP inhibitor. This combination leverages complementary mechanisms of action: olaparib inhibits PARP enzymes crucial for DNA repair, causing synthetic lethality in tumors with homologous recombination repair deficiencies (particularly those with BRCA1/2 mutations), while atezolizumab blocks PD-L1/PD-1 interaction, enhancing anti-tumor immune responses. The combination is being investigated based on evidence that DNA damage induced by PARP inhibition can stimulate immune responses through STING-dependent pathways, potentially making tumors more susceptible to immune checkpoint inhibition.